Top 5 Highlights From the 2016 ASCO GI Cancers Symposium

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Benjamin J. Golas, MD

June 30th 2025

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

ONCOLOGY Staff

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

Related Content

$The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.$

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Benjamin J. Golas, MD

June 30th 2025

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

ONCOLOGY Staff